The cost‐effectiveness of population <i>Helicobacter pylori</i> screening and treatment: a Markov model using economic data from a randomized controlled trial

Abstract

Modelling suggests that population H. pylori screening and treatment are likely to be cost-effective and could be the first cost-neutral screening programme. This provides a further mandate for clinical trials to evaluate the efficacy of population H. pylori screening and treatment in preventing mortality from gastric cancer and peptic ulcer disease.